$SLV Long 50 JUL callsWent long 50 JUL SLV 23.5 calls.
Nice looking chart and I like the R/R on a move to at least the top of the box. Will reduce the position there and manage on price reaction.
Mental stop just below 30 wk MA.
Nice consolidation with accumulation type buying, cup and handle with a good retrace from the JAN to MAR move, I think it's going for next leg higher.
A break above the box should expect a massive move, as this has been digesting since AUG 2020.
If calls go farther ITM may sell bi-weekly calls against them to reduce my cost basis, playing it day by day week by week.
Miners and Metals look good overall, many above 30wk MA.
Cheers
Phase2
$ENTX Entera Bio Ltd Announces Positive Topline EB613 Phase 2Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data
‒ Final Analysis of 6-Month Data, Including Change in Bone Mineral Density, Expected in Q2:21
‒ The trial’s primary endpoint was met - the complete 3-month results from the trial showed a significant increase in the P1NP biomarker in the 2.5 mg dose group after 3 months of treatment (P <0.04) as compared to placebo.
‒ Similar to the increase in P1NP, a significant increase in Osteocalcin was also observed in the 2.5 mg group after 3 months (P <0.01).
‒ In line with a potential anabolic effect, a significant decrease in CTX was observed after 3 months of treatment (P <0.015). The decrease in CTX taken together with the increase in P1NP and Osteocalcin would indicate a potential positive impact on BMDand a reduced risk of fractures, which is the goal of an anabolic osteoporosis treatment.
‒ Entera intends to submit the full dataset for publication and/or presentation at an upcoming medical conference.
MGEN Done Going Down Or Just A Pit Stop?MGEN has been getting hammered lately. Not one single green close in the last few weeks. Friday was the first, somewhat green close and that ain't saying much. But trading action was interesting.
"riday’s action was something much different than what the penny stock had seen during the 2 weeks prior. It was the first trading day that MGEN shares didn’t close red. If you look at the chart, since October 9th, the penny stock saw a red close every day...Furthermore, trading action continued to push shares higher during after-hours on Friday."
Original Quote Source: 5 Penny Stocks On Robinhood To Buy Under $2; Are They Too Risky?
$SELB Beats Earnings by .10/Phase 2 Results/Cash into 2020Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19,
interim six-month data expected in 4Q19
Collaboration with CureCN projected to dose first patient with combination of ImmTOR + AAV
gene therapy candidate in 2H19
Company raises $33M in gross offering proceeds and $31.3M in net proceeds in 1Q19, cash
runway into 1Q20
“During 2018 we laid a strong groundwork for a year of execution in 2019. We kicked off the year by
streamlining the company through a corporate restructuring, which is projected to cut our cash burn rate
by 19%. We then completed an equity fundraise of approximately $33 million in gross proceeds and
$31.3 million in net proceeds, and anticipate reporting key milestones for both our chronic refractory
gout and gene therapy programs. We continue to believe that our lead program, SEL-212, has the
potential to address several unmet needs in chronic refractory gout patients, including sustained serum
uric acid reduction, reduced painful flares and once monthly dosing, and we look forward to initiating
the planned six-month head-to-head (COMPARE) clinical trial against Krystexxa this month,” said Carsten
Brunn, Ph.D., President and CEO of Selecta. “We also look forward to further advancing our ImmTOR +
AAV gene therapy combination product candidate in Crigler-Najjar Syndrome in collaboration with
CureCN in the second half of the year and identifying other ways to advance our ImmTOR platform and
grow our strategic partnerships.”
Effective December 1, 2018, Carsten Brunn, Ph.D., assumed
the role of President and CEO of Selecta, following his previous position as President of
Pharmaceuticals for the Americas Region and member of the Global Pharmaceutical Executive
Committee at Bayer.
Reported Phase 2 Data: Selecta has reported data from its Phase 2 trial showing that 66% of
evaluable patients (21/32), maintained serum uric acid (sUA) levels of <6mg/dL after five oncemonthly treatments of SEL-212 at doses of 0.1 or 0.15 mg/kg of ImmTOR in combination with
0.2mg/kg of pegadricase. Furthermore, reduced total urate burden and lowered flare rates and
severity were observed in the Phase 2 clinical trial, and SEL-212 continued to be generally well
tolerated.
Collaboration with CureCN Consortium Projected to Dose First Patient in 2H19: In September
2018, Selecta announced a collaboration with CureCN, a European consortium, for an
ImmTOR+AAV gene therapy combination product candidate in Crigler-Najjar Syndrome, building
upon preclinical work that was published together with Genethon in Nature Communications in
October 2018. Selecta expects CureCN to initiate preclinical toxicology studies in the first half of
2019 and for the combination product candidate to enter the clinic in the second half of 2019.
Selecta expects to initiate a Phase 2 head-to-head (COMPARE) clinical trial of SEL-212,
compared to the current FDA-approved uricase therapy, Krystexxa, in the first quarter of 2019.
An interim six-month data readout is projected for the fourth quarter of 2019, with a full statistical data analysis expected in the first quarter of 2020. The results of the COMPARE trial are expected to inform the design of the planned Phase 3 clinical trial of SEL-212, which the company plans to initiate in the fourth quarter of 2019.
Cash Position: Selecta had $37.7 million in cash, cash equivalents and restricted cash as of December
31, 2018, which compares to cash, cash equivalents and short-term investments of $50.5 million at
September 30, 2018. The company currently has a cash runway into the first quarter of 2020, which
includes proceeds net of underwriting discounts and commissions of $31.3 million from the
company’s recent follow-on offering in January 2019.
Corporate Restructuring Completed in January 2019: Selecta completed a corporate
restructuring that reduced the company’s workforce by 36 percent as of January 3, 2019. This
reduction, coupled with a reprioritization of the company’s pipeline programs, is projected to
reduce the yearly cash burn by 19 percent.
Successfully Completed a $33.3 Million Public Offering; Providing Cash Runway into 1Q20: In
January 2019, Selecta completed an underwritten public offering of 22,188,706 shares of its
common stock, at a price to public of $1.50 per share, resulting in net proceeds to Selecta of
$31.3 million, after deducting underwriting discounts and commissions.